首页> 外国专利> Cholesteryl ester vesicles loading peptides, proteins and nucleic acids into chylomicrons and body cells

Cholesteryl ester vesicles loading peptides, proteins and nucleic acids into chylomicrons and body cells

机译:胆固醇酯囊泡将肽,蛋白质和核酸加载到乳糜微粒和人体细胞中

摘要

The present invention is directed to one or more macromolecules in a lipid vesicle oral formulation which targets intracellular receptors, in particular for peptides, proteins, nucleic acids and mixtures thereof, optionally in combination with small molecules. The invention encapsulates said macromolecules in a neutral lipid vesicle comprised of one or more cholesteryl esters. Unique properties of macromolecules encapsulated in said vesicles include high oral bioavailability, defined herein as in at least 50%, i.e., often in excess of 50% on the basis of oral to parenteral AUC. Non-limiting examples are provided, for large hydrophilic molecules such as peptides, proteins and nucleic acids which heretofore have been very poorly absorbed by the mammalian intestine. In prior art; said molecules are generally less than 25% bioavailable, even with protective coatings and optionally absorption enhancing component substances in the formulation. An additional feature of the present invention is high tissue concentrations after oral use, a result of rapid uptake of cholestosomes delivered by chylomicrons to body cells. A preferred embodiment is disclosed for insulin, where with eholestosome encapsulation oral bioavailability is at least 66%. Prior to the present invention, oral bioavailability of insulin and other peptides and proteins was maximally 25% and usually between 5% and 10%. Additional preferred examples are provided for one or more macromolecules useful in the treatment of cancer and in particular intracellular targeting in the practice of cancer immunotherapeutics.
机译:本发明涉及脂质囊泡口服制剂中的一种或多种大分子,其靶向细胞内受体,特别是肽,蛋白质,核酸及其混合物,任选地与小分子结合。本发明将所述大分子包封在由一种或多种胆固醇酯组成的中性脂质囊泡中。包封在所述囊泡中的大分子的独特性质包括高口服生物利用度,本文定义为口服至肠胃外AUC的至少50%,即通常超过50%。对于迄今被哺乳动物肠道吸收非常弱的大亲水分子,例如肽,蛋白质和核酸,提供了非限制性实例。在现有技术中;所述分子即使在制剂中具有保护性涂层和任选的吸收增强成分物质,其生物利​​用度也通常小于25%。本发明的另一个特征是口服使用后的高组织浓度,这是乳糜微粒将胆甾醇快速摄取到体细胞的结果。公开了胰岛素的一个优选实施方案,其中在包裹有脂质体的情况下,口服生物利用度至少为66%。在本发明之前,胰岛素和其他肽和蛋白质的口服生物利用度最大为25%,通常在5%和10%之间。提供了用于在癌症免疫疗法的实践中用于治疗癌症,特别是细胞内靶向的一种或多种大分子的另外的优选实例。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号